Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related deaths
worldwide. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR‑TKIs) have …

Background/Aim: Acquired resistance to epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs) has posed serious clinical problems in the treatment of lung …

Abstract Effects of estrogen receptorβ (ERβ) localization on epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) in advanced non-small cell lung cancer (NSCLC) are …

There is growing evidence that estrogen receptors (ER) are expressed in lung cancer cells,
and are able to interact with the epidermal growth factor receptor (EGFR) signaling pathway …

Introduction Estrogen receptor (ER) signaling and its interaction with epidermal growth factor
receptor (EGFR) is a potential therapeutic target in non–small-cell lung cancer (NSCLC). To …

The present study assessed whether estrogen receptor (ER) β1 is associated with the
survival of patients with advanced lung adenocarcinoma, with or without mutations of the …

Background: Positive expression of estrogen receptor (ER) beta is correlated with a
favorable prognosis for patients with epidermal growth factor receptor (EGFR) mutations and …

EGFR mutation-induced drug resistance has become a major threat to the treatment of non-
small-cell lung carcinoma. Essentially, the resistance mechanism involves modifications of …

A signaling pathway that is frequently deregulated in human carcinomas and has been
explored as a therapeutic target involves the activation of the epidermal growth factor …

Identifying new effective therapeutic treatments for lung cancer is critical to improving overall
patient survival. We have targeted both the estrogen receptor (ER) and the epidermal growth …